Skip to main content
. 2017 Apr 11;12(4):e0175466. doi: 10.1371/journal.pone.0175466

Fig 5. The combination of chelerythrine and erlotinib significantly inhibited EFGR downstream signal and activated PARP.

Fig 5

A. Cells were treated with eroltinib, chelerythrine or combination of both in a serum free medium for 12 hours before stimulation with EGF for 10 minutes. Cell lysates were collected for western blot analysis of p-STAT3 (S727)/STAT3, p-ERK1/2/ERK1/2, p-p38 MAPK/p38 MAPK, p-Bad/Bad, and β-tubulin was used as a loading control. B. Activation of the poly (ADP-ribose) polymerase (PARP). Cells were treated with eroltinib, chelerythrine or a combination of both in the growth media for 24 hours. Cell lysates were collected for western blot analysis of PARP, and GAPDH was used as a loading control. 3 independent experiments were performed. C. EGFR expression on three NSCLC cells.